Alyeska Investment Group
ANTX icon

Alyeska Investment Group’s AN2 Therapeutics ANTX Stock Holding History

Alyeska Investment Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100,000
Closed -$215K – 525
2024
Q2 		$215K Hold
100,000
– – ﹤0.01% 530
2024
Q1 		$325K Buy
100,000
+50,000
+100% +$544K ﹤0.01% 437
2023
Q4 		$1.02M Hold
50,000
– – 0.01% 407
2023
Q3 		$804K Sell
50,000
-48,426
-49% -$548K 0.01% 429
2023
Q2 		$837K Buy
98,426
+50,000
+103% +$359K 0.01% 465
2023
Q1 		$478K Hold
48,426
– – ﹤0.01% 416
2022
Q4 		$462K Sell
48,426
-57,292
-54% -$767K ﹤0.01% 376
2022
Q3 		$1.84M Sell
105,718
-19,282
-15% -$225K 0.02% 322
2022
Q2 		$969K Hold
125,000
– – 0.01% 497
2022
Q1 		$1.88M Buy
+125,000
New +$1.9M 0.02% 438

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's ANTX Position: Q3 2024 in Review

Alyeska Investment Group sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 100,000 shares — an estimated $215K sold.

Alyeska Investment Group first reported a position in ANTX in Q1 2022 and held it in 10 quarters. The position peaked at $1.88M in Q1 2022. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Alyeska Investment Group reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 100,000 AN2 Therapeutics shares in Q3 2024, an estimated $215K.
  • Alyeska Investment Group first reported a position in AN2 Therapeutics in Q1 2022 and held it in 10 quarters.
  • Alyeska Investment Group's AN2 Therapeutics position peaked at $1.88M in Q1 2022.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.